<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Olaparib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Olaparib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Olaparib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="98855" href="/d/html/98855.html" rel="external">see "Olaparib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26730986"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lynparza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871861"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lynparza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26641538"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, PARP Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F26853200"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Do not initiate treatment with olaparib until after hematologic toxicity due to prior chemotherapy has resolved to ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Due to differences in dosing and bioavailability, in international markets where capsules may be available, do <b>not</b> substitute capsules for tablets (or vice versa).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Select patients for therapy based on an approved olaparib companion diagnostic test for detection of genetic mutations or biomarkers.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ab1d188-edab-41a5-9ce7-62e129b541dd">Breast cancer, early, high-risk, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, early, high-risk, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated, adjuvant therapy: Oral: </b>
<i>Tablets: </i>300 mg twice daily for 1 year or until disease progression or unacceptable toxicity, whichever occurs first (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36228963','lexi-content-ref-34081848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36228963','lexi-content-ref-34081848'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1d4243d-fc82-408c-a728-4ffb4fe82d68">Breast cancer, metastatic, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated<b>:</b></b>
<b>Oral:</b>
<i>Tablets: </i>300 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28578601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28578601'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd97a245-d4b5-4760-aef1-a3bebd7ba296">Ovarian cancer, advanced, BRCA-mutated, first-line maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced, </b>
<i>
<b>BRCA</b></i>
<b>-mutated</b>
<b>
<b>, first-line maintenance therapy (monotherapy)</b>: Oral:</b>
<i>Tablets: </i>300 mg twice daily until disease progression or unacceptable toxicity or completion of 2 years of therapy. Patients with a complete response (no radiologic evidence of disease) at 2 years should discontinue olaparib; patients with evidence of disease at 2 years may continue treatment (beyond 2 years) if further olaparib treatment may provide benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36150092','lexi-content-ref-30345884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36150092','lexi-content-ref-30345884'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="776e7c7c-7ba2-4a06-9898-e46c83545b16">Ovarian cancer, advanced, homologous recombination deficient-positive, first-line maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced, homologous recombination deficient-positive, first-line maintenance therapy (combination therapy): Oral:</b>
<i>Tablets: </i>300 mg twice daily (in combination with bevacizumab) until disease progression or unacceptable toxicity or completion of 2 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31851799','lexi-content-ref-37211045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31851799','lexi-content-ref-37211045'])">Ref</a></span>). Patients with a complete response (no radiologic evidence of disease) at 2 years should discontinue olaparib; patients with evidence of disease at 2 years may continue treatment (beyond 2 years) if further olaparib treatment may provide benefit. Bevacizumab duration is for a total of 15 months (including when administered with chemotherapy as well as maintenance).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a35c2b1f-b082-4713-b962-831045789eb0">Ovarian cancer, recurrent, <i>BRCA</i>-mutated, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, recurrent, <i>BRCA</i>-mutated, maintenance therapy:</b>
<b>Oral:</b>
<i>Tablets:</i> 300 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33743851','lexi-content-ref-28754483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33743851','lexi-content-ref-28754483'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fb3f87dd-80c0-4cde-8885-3fb1486c64b8">Pancreatic cancer, metastatic, germline <i>BRCA</i>-mutated, first-line maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, metastatic, germline <i>BRCA</i>-mutated</b>
<b>, first-line maintenance therapy:</b>
<b>Oral:</b>
<i>Tablets: </i>300 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31157963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31157963'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9addb499-e701-4f63-902d-60aef5057685">Prostate cancer, metastatic, castration resistant, <i>BRCA</i>-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant, </b>
<i>
<b>BRCA</b></i>
<b>-mutated: Oral:</b>
<i>Tablets:</i> 300 mg twice daily (in combination with abiraterone and prednisone or prednisolone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clarke.1','lexi-content-ref-37714168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clarke.1','lexi-content-ref-37714168'])">Ref</a></span>). Patients should also receive a gonadotropin-releasing hormone analog or have had bilateral orchiectomy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b765752-eb54-42be-a039-230556cdda8e">Prostate cancer, metastatic, castration resistant, homologous recombination repair gene-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant, homologous recombination repair gene-mutated: Oral:</b>
<i>Tablets: </i>300 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32343890','lexi-content-ref-32955174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32343890','lexi-content-ref-32955174'])">Ref</a></span>). Patients should also receive a gonadotropin-releasing hormone analog or have had bilateral orchiectomy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, administer the next dose at its scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990956"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Kidney function estimated by Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 31 to 50 mL/minute: <i>Tablets:</i> Reduce dose to 200 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≤30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage kidney disease: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988351"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Turcotte-Pugh classes A, B): Tablets: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Turcotte-Pugh class C): <i>Tablets</i>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F26853204"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Consider therapy interruption or dose reduction if adverse reactions occur.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Olaparib (Tablet) Dosage Reduction Levels </b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage reduction levels</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Recommended olaparib dosage and schedule </b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initial (usual) dosage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">First dosage reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">250 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Second dosage reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg twice daily</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Olaparib (Tablet) Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Olaparib dosage modification</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> ASCO [Tew 2020]</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Anemia (in the treatment ovarian cancer)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 mg/dL and/or requiring a blood transfusion for symptom relief</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Monitor patient<sup>a</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Repeated episodes of anemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reduce olaparib dose to avoid repeated transfusion<sup>a</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia (in the treatment ovarian cancer)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (lasting ≥5 to 7 days or associated with fever)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold olaparib until recovery of infection and granulocyte count; resume olaparib at a reduced dose<sup>a</sup>.</p>
<p style="text-indent:0em;text-align:left;">WBC growth factor support may be used while olaparib is withheld for neutropenia; however, growth factors are not indicated during daily olaparib dosing<sup>a</sup>.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Thrombocytopenia (in the treatment ovarian cancer)</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3 to 4</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold olaparib until resolution; resume olaparib at a reduced dose.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Persistent or significant bleeding despite dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue olaparib.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Prolonged</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold olaparib and monitor blood counts weekly.</p>
<p style="text-indent:0em;text-align:left;">If counts do not recover to ≤ grade 1 after 4 weeks, further evaluation (including bone marrow and cytogenetic analyses) is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Secondary acute myeloid leukemia/ myelodysplastic syndrome</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Confirmed</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue olaparib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">GI toxicity (in the treatment of ovarian cancer)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Persistent nausea requiring daily antiemetics, resulting in performance status reduction and/or resulting in &gt;5% weight loss</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Consider olaparib dose reduction<sup>a</sup>.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Pulmonary toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pneumonitis (suspected)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold olaparib and evaluate promptly for new or worsening respiratory symptoms (eg, cough, dyspnea, fever, wheezing) or for radiologic abnormalities</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pneumonitis (confirmed)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Discontinue olaparib and treat the patient appropriately.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Venous thromboembolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Venous thrombosis and/or pulmonary embolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Treat as medically appropriate; may include long-term anticoagulation as clinically indicated.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F26853201"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F26970623"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (45%; upper abdominal pain: 5% to 7%), constipation (23% to 28%), decreased appetite (13% to 25%), diarrhea (18% to 37%; grades 3/4: ≤3%), dysgeusia (11% to 27%), dyspepsia (5% to 17%), nausea (45% to 77%; grades 3/4: ≤3%), stomatitis (10% to 20%; grades 3/4: ≤1%), vomiting (20% to 40%; grades 3/4: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (24% to 44%; grades 3/4: 9% to 21%), increased MCV (≤89%), leukopenia (5% to 17%; grades 3/4: 3%), neutropenia (12% to 19%; grades 3/4: 4% to 6%), thrombocytopenia (4% to 14%; grades 3/4: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (≤36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (7% to 20%), fatigue (67%; including asthenia), headache (7% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤30%), back pain (19%), myalgia (≤30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2% to 99%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≤28%), cough (9% to 18%), dyspnea (4% to 15%), nasopharyngitis (≤36%), rhinitis (≤36%), sinusitis (≤36%), upper respiratory tract infection (≤36%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (8%), venous thromboembolism (≤5%; including severe pulmonary embolism)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (1% to 7%), myelodysplastic syndrome (≤8%), myeloid leukemia (acute: ≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Respiratory: Pneumonitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema nodosum</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p></div>
<div class="block coi drugH1Div" id="F26641541"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to olaparib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F26853178"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including rash, dermatitis, and angioedema, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Pneumonitis (including some fatalities) has occurred rarely in studies of single-agent olaparib in patients with various cancers. New or worsening respiratory symptoms include cough, dyspnea, fever, and/or wheezing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) have been reported (rarely) in clinical trials of patients with various cancers who received olaparib (as a single agent or as part of a combination regimen), including fatal cases. The median duration of olaparib therapy prior to development of the secondary cancers was ~2 years (range: &lt;6 months to &gt;4 years). All patients had received prior chemotherapy with platinum agents and/or other DNA-damaging agents, including radiation therapy. If prolonged hematologic toxicity occurs and blood counts do not recover to ≤ grade 1 after 4 weeks, further evaluation (including bone marrow and cytogenetic analyses) is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Venous thromboembolism, including severe or fatal pulmonary embolism, have been reported. In studies of patients with metastatic castration-resistant prostate cancer who received olaparib, venous thromboembolic events occurred at a higher rate compared to patients in the control arms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for olaparib therapy based on genetic mutations, biomarker status, and tumor sample type. Information on approved tests for the detection of genetic mutations may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=98761" target="_blank">http://www.fda.gov/companiondiagnostics</a>. If testing fails or tissue sample is unavailable, or when germline testing is negative, consider using an alternative test (if available).</p></div>
<div class="block foc drugH1Div" id="F26730987"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lynparza: 100 mg, 150 mg</p></div>
<div class="block geq drugH1Div" id="F26730985"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26844485"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lynparza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $163.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $163.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871862"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lynparza: 50 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lynparza: 100 mg, 150 mg</p></div>
<div class="block accres drugH1Div" id="F26853157"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Olaparib is available through the authorized specialty pharmacy providers. For further information on patient assistance, product availability, and prescribing instructions, please refer to the following website: https://providerportal.myaccess360.com or call 1-844-275-2360.</p></div>
<div class="block adm drugH1Div" id="F26853207"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer approximately every 12 hours with or without food. Swallow tablets whole; do not chew, crush, dissolve, or divide tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Based on a pharmacokinetic study (in tablets), the rate of absorption was slower and the peak exposure was decreased when administered with a high-fat meal; however, the extent of absorption was not affected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Nausea and vomiting were reported more frequently when olaparib was administered in a fasted state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242220'])">Ref</a></span>). Administering olaparib after a small meal or snack may help alleviate potential nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clarke.1','lexi-content-ref-32343890','lexi-content-ref-36228963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clarke.1','lexi-content-ref-32343890','lexi-content-ref-36228963'])">Ref</a></span>). Consider providing patients with antiemetic therapy for at home use as needed on days of olaparib dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36228963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36228963'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49133402"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Olaparib may cause reproductive toxicity, teratogenicity, and genotoxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F26854741"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Lynparza tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F208558s028lbl.pdf%23page%3D58&amp;token=h2zkkVpOeaUL8Mh6v92pEuzBufG6zw0X9wgpvk56g%2FvOMQnq03VlMjODoVmprlA37%2FBtQtsAmY4c3uOAd6E8TwVGXxvAlVnIMCuSE0GjYwktHEBGNrOsismt%2FEoGfJaU&amp;TOPIC_ID=98761" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf#page=58</a></p></div>
<div class="block use drugH1Div" id="F26641540"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, early, high-risk, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated, adjuvant therapy: </b>Tablets: Adjuvant treatment of deleterious or suspected deleterious germline <i>BRCA</i>-mutated (g<i>BRCA</i>m), <i>HER2</i>-negative, high-risk, early breast cancer in adults who have been treated with neoadjuvant or adjuvant chemotherapy (select patients for therapy based on an approved olaparib companion diagnostic test for g<i>BRCA1</i>m or g<i>BRCA2</i>m in blood specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated:</b> Tablets: Treatment of deleterious or suspected deleterious g<i>BRCA</i>m, <i>HER2</i>-negative metastatic breast cancer in adults who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor-positive disease should have received a prior endocrine therapy or be considered inappropriate for endocrine therapy (select patients for therapy based on an approved olaparib companion diagnostic test for g<i>BRCA1</i>m or g<i>BRCA2</i>m in blood specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced, </b>
<i>
<b>BRCA</b></i>
<b>-mutated, first-line maintenance therapy</b>: Tablets: First-line maintenance treatment (as monotherapy) of deleterious or suspected deleterious<i> gBRCA</i>m or somatic <i>BRCA</i>-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who are in complete or partial response to first-line, platinum-based chemotherapy (select patients for therapy based on an approved olaparib companion diagnostic test for <i>BRCA1</i>m or <i>BRCA2</i>m in tumor or blood specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced, homologous recombination deficient-positive, first-line maintenance therapy:</b> Tablets: First-line maintenance treatment (in combination with bevacizumab) of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who are in complete or partial response to first-line, platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)–positive status, defined by either a deleterious or suspected deleterious <i>BRCA</i> mutation and/or genomic instability (select patients for therapy based on an approved olaparib companion diagnostic test for <i>BRCA1</i>m, <i>BRCA2</i>m, and/or genomic instability in tumor specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, recurrent, <i>BRCA</i>-mutated, maintenance therapy</b>: Tablets: Maintenance treatment (as monotherapy) of deleterious or suspected deleterious g<i>BRCA</i>m or somatic <i>BRCA</i>-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who are in complete or partial response to platinum-based chemotherapy (select patients for therapy based on an approved olaparib companion diagnostic test for <i>BRCA1</i>m or <i>BRCA2</i>m in tumor or blood specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, metastatic, germline <i>BRCA</i>-mutated, first-line maintenance therapy: </b>Tablets: First-line maintenance treatment of deleterious or suspected deleterious g<i>BRCA</i>m metastatic pancreatic adenocarcinoma in adults whose disease has not progressed on at least 16 weeks of a first-line, platinum-based chemotherapy regimen (select patients for therapy based on an approved olaparib companion diagnostic test for g<i>BRCA1</i>m or g<i>BRCA2</i>m in blood specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant, </b>
<i>
<b>BRCA</b></i>
<b>-mutated: </b>Tablets: Treatment of deleterious or suspected deleterious <i>BRCA</i>-mutated metastatic castration-resistant prostate cancer (mCRPC) in adults (in combination with abiraterone and prednisone or prednisolone) (select patients for therapy based on an approved olaparib companion diagnostic test for <i>BRCA1</i>m or <i>BRCA2</i>m in tumor, blood, or plasma [ctDNA] specimen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration-resistant, homologous recombination repair gene-mutated: </b>Tablets: Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer in adults who have progressed following prior enzalutamide or abiraterone treatment (select patients for therapy based on an approved olaparib companion diagnostic test for <i>ATM</i>m, <i>BRCA1</i>m, <i>BRCA2</i>m, <i>BARD1</i>m, <i>BRIP1</i>m, <i>CDK12</i>m, <i>CHEK1</i>m, <i>CHEK2</i>m, <i>FANCL</i>m, <i>PALB2</i>m, <i>RAD51B</i>m, <i>RAD51C</i>m, <i>RAD51D</i>m, or <i>RAD54L</i>m in tumor specimen, for g<i>BRCA1</i>m or g<i>BRCA2</i>m in blood specimen, or for <i>ATM</i>m, <i>BRCA1</i>m, or <i>BRCA2</i>m in plasma [ctDNA] specimen).</p></div>
<div class="block mst drugH1Div" id="F26853154"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Olaparib may be confused with niraparib, osimertinib, rucaparib, talazoparib.</p>
<p style="text-indent:-2em;margin-left:4em;">Lynparza may be confused with lenvatinib, Lenvima.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26736588"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F26736585"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bitter Orange: May increase the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Olaparib. Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Olaparib. Management: Avoid use of strong CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 100 mg twice daily and the dose of olaparib capsules should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: May enhance the myelosuppressive effect of Olaparib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F26853181"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Coadministration with grapefruit, grapefruit juice, Seville oranges, or Seville orange juice may increase olaparib plasma concentrations. Management: Avoid concomitant administration with grapefruit, grapefruit juice, Seville oranges, or Seville orange juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308556"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use highly effective contraception during therapy and for 6 months after the last olaparib dose. Patients with partners who could become or are pregnant should use effective contraception during treatment and for 3 months after the last olaparib dose; patients also should not donate sperm during therapy and for 3 months following the last olaparib dose.</p></div>
<div class="block pri drugH1Div" id="F26853175"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to olaparib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F26853177"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if olaparib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that patients should not breastfeed during treatment and for 1 month after the last olaparib dose.</p></div>
<div class="block dic drugH1Div" id="F26853206"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit, grapefruit juice, Seville oranges, or Seville orange juice.</p></div>
<div class="block mop drugH1Div" id="F26853209"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Testing for genetic mutations or biomarker status (see table); CBC at baseline and monthly thereafter, or as clinically indicated (weekly until recovery for prolonged hematologic toxicity), renal function. Verify pregnancy status (prior to treatment initiation in patients who could become pregnant). Monitor for signs/symptoms of venous thrombosis, pulmonary embolism, and pneumonitis (evaluate promptly for new or worsening respiratory symptoms such as cough, dyspnea, fever, wheezing, or for radiologic abnormalities). Monitor for signs of acute myeloid leukemia/myelodysplastic syndrome (if prolonged hematologic toxicity occurs and blood counts do not recover to ≤ grade 1 after 4 weeks, further evaluation, including bone marrow and cytogenetic analyses is necessary). Monitor adherence.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left" colspan="5">
<p style="text-indent:0em;">Recommended Testing for Genetic Mutations or Biomarker Status in Patients Treated with Olaparib</p></th></tr>
<tr>
<th align="left" rowspan="2">
<p style="text-indent:0em;">Indication</p></th>
<th align="left" rowspan="2">
<p style="text-indent:0em;">Biomarker</p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">Sample type</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Tumor</p></th>
<th align="left">
<p style="text-indent:0em;">Blood</p></th>
<th align="left">
<p style="text-indent:0em;">Plasma (ctDNA)</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> HRD = Homologous recombination deficiency; HRR = homologous recombination repair</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer, early, high-risk, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated, adjuvant therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">g<i>BRCA1</i>m, g<i>BRCA2</i>m</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer, metastatic, <i>HER2</i>-negative, germline <i>BRCA</i>-mutated</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">g<i>BRCA1</i>m, g<i>BRCA2</i>m</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ovarian cancer, advanced, <i>BRCA</i>-mutated, first-line maintenance therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>BRCA1</i>m, <i>BRCA2</i>m</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ovarian cancer, recurrent, <i>BRCA</i>-mutated, maintenance</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>BRCA1</i>m, <i>BRCA2</i>m</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ovarian cancer, advanced, HRD<sup>a</sup>-positive, first-line maintenance therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>BRCA1</i>m, <i>BRCA2</i>m and/or genomic instability</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pancreatic cancer, metastatic, germline <i>BRCA</i>-mutated, first-line maintenance therapy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">g<i>BRCA1</i>m, g<i>BRCA2</i>m</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Prostate cancer, metastatic, castration resistant, <i>BRCA</i>-mutated (combination therapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>BRCA1</i>m, <i>BRCA2</i>m</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Prostate cancer, metastatic, castration-resistant, HRR<sup>a</sup> gene-mutated</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>ATM</i>m, <i>BRCA1</i>m, <i>BRCA2</i>m, <i>BARD1</i>m, <i>BRIP1</i>m, <i>CDK12</i>m, <i>CHEK1</i>m, <i>CHEK2</i>m, <i>FANCL</i>m, <i>PALB2</i>m, <i>RAD51B</i>m, <i>RAD51C</i>m, <i>RAD51D</i>m, <i>RAD54L</i>m</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">g<i>BRCA1</i>m, g<i>BRCA2</i>m</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>ATM</i>m, <i>BRCA1</i>m, <i>BRCA2</i>m</p></td>
<td align="left"></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">X</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F26853183"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Olaparib is a poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP1, PARP2, and PARP3. PARP enzymes are involved in DNA transcription, cell cycle regulation, and DNA repair. Olaparib is a potent oral PARP inhibitor which induces synthetic lethality in <i>BRCA1/2</i> deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death (Ledermann 2012). In prostate cancer models, PARP1 has demonstrated contribution to regulation of androgen receptor activity; combining olaparib with androgen receptor inhibition results in cytotoxicity (in vitro) and antitumor activity.</p></div>
<div class="block phk drugH1Div" id="F26853186"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; delayed with a high-fat/high-calorie meal (extent of absorption not significantly altered).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Tablet: 158 ± 136 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~82%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, terminal: Tablet: 14.9 ± 8.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Tablet: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (44%, mostly as metabolites); feces (42%, mostly as metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Tablet: 7.4 ± 3.9 hours.</p></div>
<div class="block phksp drugH1Div" id="F51154909"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: The mean AUC and C<sub>max</sub> increased by 24% and 15%, respectively, in patients with mild renal impairment (CrCl 51 to 80 mL/minute), and by 44% and 26%, respectively, in patients with moderate renal impairment (CrCl 31 to 50 mL/minute) compared with patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Tablets: The mean AUC and the mean C<sub>max</sub> increased by 15% and 13%, respectively, in patients with mild impairment (Child-Pugh class A), compared with patients with normal hepatic function. The mean AUC increased by 8% and the mean C<sub>max </sub>decreased by 13% in patients with moderate impairment (Child-Pugh class B), compared with patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26732987"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Inpoza | Olanib | Olaparix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bracanat | Lynparza</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Linparza</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lynparza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarke.1">
<a name="Clarke.1"></a>Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. <i>NEJM Evidence</i>. Published online June 3, 2022. doi:https://evidence.nejm.org/doi/10.1056/EVIDoa2200043</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32343890">
<a name="32343890"></a>de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. <i>N Engl J Med</i>. 2020;382(22):2091‐2102. doi:10.1056/NEJMoa1911440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/32343890/pubmed" id="32343890" target="_blank">32343890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36228963">
<a name="36228963"></a>Geyer CE Jr, Garber JE, Gelber RD, et al; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. <i>Ann Oncol</i>. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/36228963/pubmed" id="36228963" target="_blank">36228963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31157963">
<a name="31157963"></a>Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. <i>N Engl J Med</i>. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/31157963/pubmed" id="31157963" target="_blank">31157963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26527784">
<a name="26527784"></a>Hesketh PJ, Bohlke K, Lyman GH, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology focused guideline update. <i>J Clin Oncol</i>. 2016;34(4):381-386. doi:10.1200/JCO.2015.64.3635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/26527784/pubmed" id="26527784" target="_blank">26527784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32955174">
<a name="32955174"></a>Hussain M, Mateo J, Fizazi K, et al; PROfound trial investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. <i>N Engl J Med</i>. 2020;383(24):2345-2357. doi:10.1056/NEJMoa2022485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/32955174/pubmed" id="32955174" target="_blank">32955174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25366685">
<a name="25366685"></a>Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <i>J Clin Oncol</i>. 2015;33(3):244-250. doi:10.1200/JCO.2014.56.2728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/25366685/pubmed" id="25366685" target="_blank">25366685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22203755">
<a name="22203755"></a>Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. <i>J Clin Oncol</i>. 2012;30(4):372-379. doi:10.1200/JCO.2011.36.9215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/22203755/pubmed" id="22203755" target="_blank">22203755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22452356">
<a name="22452356"></a>Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. <i>N Engl J Med</i>. 2012;366(15):1382-1392. doi:10.1056/NEJMoa1105535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/22452356/pubmed" id="22452356" target="_blank">22452356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lynparza.1">
<a name="Lynparza.1"></a>Lynparza (olaparib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lynparza.2">
<a name="Lynparza.2"></a>Lynparza (olaparib) tablets [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30345884">
<a name="30345884"></a>Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. <i>N Engl J Med</i>. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/30345884/pubmed" id="30345884" target="_blank">30345884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242220">
<a name="26242220"></a>Plummer R, Swaisland H, Leunen K, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer Chemother Pharmacol</i>. 2015;76(4):723-729. doi:10.1007/s00280-015-2836-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/26242220/pubmed" id="26242220" target="_blank">26242220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33743851">
<a name="33743851"></a>Poveda A, Floquet A, Ledermann JA, et al; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(5):620-631. doi:10.1016/S1470-2045(21)00073-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/33743851/pubmed" id="33743851" target="_blank">33743851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28754483">
<a name="28754483"></a>Pujade-Lauraine E, Ledermann JA, Selle F, et al; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [published correction appears in: <i>Lancet Oncol</i>. 2017;18(9):e510.]. <i>Lancet Oncol</i>. 2017;18(9):1274-1284. doi:10.1016/S1470-2045(17)30469-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/28754483/pubmed" id="28754483" target="_blank">28754483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37211045">
<a name="37211045"></a>Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. <i>Ann Oncol</i>. 2023;34(8):681-692. doi:10.1016/j.annonc.2023.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/37211045/pubmed" id="37211045" target="_blank">37211045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31851799">
<a name="31851799"></a>Ray-Coquard I, Pautier P, Pignata S, et al; PAOLA-1 Investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. <i>N Engl J Med</i>. 2019;381(25):2416‐2428. doi:10.1056/NEJMoa1911361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/31851799/pubmed" id="31851799" target="_blank">31851799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28578601">
<a name="28578601"></a>Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. <i>N Engl J Med</i>. 2017;377(6):523-533. doi:10.1056/NEJMoa1706450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/28578601/pubmed" id="28578601" target="_blank">28578601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol.</i> 2016;27(suppl 5):v119-v133. doi:10.1093/annonc/mdw270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37714168">
<a name="37714168"></a>Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i>. 2023;24(10):1094-1108. doi:10.1016/S1470-2045(23)00382-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/37714168/pubmed" id="37714168" target="_blank">37714168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32790492">
<a name="32790492"></a>Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(30):3468-3493. doi:10.1200/JCO.20.01924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/32790492/pubmed" id="32790492" target="_blank">32790492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36150092">
<a name="36150092"></a>Tew WP, Lacchetti C, Kohn EC; PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. <i>J Clin Oncol</i>. 2022:JCO2201934. doi:10.1200/JCO.22.01934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/36150092/pubmed" id="36150092" target="_blank">36150092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34081848">
<a name="34081848"></a>Tutt ANJ, Garber JE, Kaufman B, et al; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with <i>BRCA1</i>- or <i>BRCA2</i>-mutated breast cancer. <i>N Engl J Med</i>. 2021;384(25):2394-2405. doi:10.1056/NEJMoa2105215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/34081848/pubmed" id="34081848" target="_blank">34081848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 98761 Version 228.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
